REG - Novacyt S.A. - AGM voting

Novacyt SAAnnouncement

03/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240603:nRSC7294Qa&default-theme=true

RNS Number : 7294Q  Novacyt S.A.  03 June 2024

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

AGM voting

 

Paris, France, and Eastleigh and Manchester, UK - 3 June 2024 - Novacyt S.A.
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics
company with a broad portfolio of integrated technologies and services, will
be holding its annual general meeting ("AGM") exclusively as an open online
meeting at 2pm CEST/1pm BST on Wednesday, 26 June 2024. As usual, and in
accordance with French corporate law, the AGM comprises both ordinary and
extraordinary resolutions. All materials can be found at
www.novacyt.com/investors (http://www.novacyt.com/investors) .

 

Shareholders are strongly encouraged to submit their votes in advance, in
accordance with the instructions in the Notice of the AGM.

 

Under French law, for the AGM and EGM meetings to be quorate at the first
attempt, shareholders representing at least 20% of the share capital and
voting rights, on ordinary resolutions, and 25% of the share capital and
voting rights, on extraordinary resolutions, must be present, represented or
have voted in advance under the conditions set out below.

 

Shareholders can vote in advance of the AGM by:

 

•    Downloading a copy of the proxy voting form from the website
www.novacyt.com/investors (http://www.novacyt.com/investors) , completing it
and returning it together with evidence of their shareholding which must be in
the form of a share certificate (attestation), either by post to the following
address: 6 avenue de Provence 75452 Paris Cedex 09, or via email to the
following address: serviceproxy@cic.fr, or investor.relations@novacyt.com, no
later than 24 June 2024 inclusive.

•     Voting on-line using the Votaccess portal
http://www.actionnaire.cic-marketsolutions.eu
(http://www.actionnaire.cic-marketsolutions.eu) if securities held on Euronext
Growth are registered with any of the following banks: CIC, Natixis, Société
Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO,
Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank, Bank of New
York or JP Morgan. The Votaccess portal will be open from 3 June 2024 to 25
June 2023 2pm BST/3pm CEST.

•    Voting on-line via a broker, nominee, bank or authorised
intermediary. Many intermediaries in the UK such as Hargreaves Lansdown are
now using the Broadridge ProxyVote on-line voting portal.

 

Shareholders can register for the AGM and access the online meeting by
visiting
https://reg.lumiengage.com/novacyt-sa-agm-2024/novacytagm2024/Site/Register
(https://reg.lumiengage.com/novacyt-sa-agm-2024/novacytagm2024/Site/Register)
. Registrations must be accompanied by formal evidence of shareholding.

 

Following registration approval, shareholders will be able to virtually attend
the AGM and vote online during the meeting if they wish, providing formal
evidence of holding has been provided prior to the meeting.

 

Shareholders who have already voted (through a proxy, via their broker,
nominee, bank, authorised intermediary, Votaccess portal or Broadridge
ProxyVote) will be allowed to attend the AGM but will not be able to vote
twice.

 

Following the meeting, a recording of the AGM will be available on the
Company's website at www.novacyt.com/investors
(http://www.novacyt.com/investors) .

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Deutsche Numis (Joint Broker)                                                                             +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Michael Palser

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Stephanie Cuthbert / Paul McManus /                                     +44 (0)7796 794 663 / +44 (0)7980 541 893

 Phillip Marriage / Alice Woodings                                        +44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com (http://www.novacyt.com) )

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical             Broad portfolio of human clinical in vitro diagnostic products, workflows and
                      services focused on three therapeutic areas:

                      ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                      tests

                      ·    Precision Medicine: DPYD genotyping assay

                      ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                      panel

 Instrumentation      Portfolio of next generation size selection DNA sample preparation platforms
                      and rapid PCR machines, including:

                      ·  Ranger® Technology: automated DNA sample preparation and target
                      enrichment technology

                      ·     MyGo: real-time quantitative PCR (qPCR) instruments

 Research Use Only    Range of services for the life sciences industry:

                      ·    Design, manufacture, and supply of high-performance qPCR assays and
                      workflows for use in human health, agriculture, veterinary and environmental,
                      to support global health organisations and the research industry

                      ·   Pharmaceutical research services: whole genome sequencing (WGS) /
                      whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the
UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and
Canada and has a commercial presence in over 65 countries. The Company is
listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris
Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMSDAFMFELSEFI